Effect of mifepristone approval on research remains to be seen.
Vastag
B
B
D000021:Abortifacient Agents, Steroidal / Q000494:pharmacology*; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry; D005260:Female; D005602:France; D005858:Germany; D006801:Humans; D008297:Male; D015735:Mifepristone / Q000494:pharmacology*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011374:Progesterone / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012109:Research Support as Topic; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000021:Abortifacient Agents, Steroidal; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D015735:Mifepristone; D011374:Progesterone